您好,欢迎您

【2024 AACR】肺癌领域重磅临床研究进展抢先看!

03月06日
整理:肿瘤资讯
来源:肿瘤资讯

美国癌症研究协会(AACR)年会是全球历史悠久、肿瘤领域最具影响力的学术盛会之一。会议关注高质量肿瘤研究及创新研究,聚焦肿瘤领域热点,汇集最前沿进展和科研成果。第115届AACR年会将于美国东部时间2024年4月5日至2024年4月10日在美国加州圣地亚哥举行。当地时间3月5日AACR官网披露摘要标题,【肿瘤资讯】为您精选肺癌领域相关重要临床研究进展。

Clinical Trials Plenary Session

CTPL04-Biomarkers: Quantifying Pharmacodynamic Modulation

摘要号:CT017 

摘要标题:FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed

Presenter:丹娜法伯癌症研究所 P. A. Jänne  

Clinical Trials Minisymposium

CTMS01-Cancer Vaccines: Ready for Prime Time?

摘要号:CT021 

摘要标题:Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC

Presenter:荷兰癌症研究所 W. Theelen

CTMS02-Advances in Immunotherapy 

摘要号:CT032

摘要标题:Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)

Presenter:昭和大学医学部 A. Horiike 

摘要号:CT034 

摘要标题:Results from phase 3 KEYLYNK-008: Pembrolizumab (pembro) with and without maintenance olaparib (ola) after first-line (1L) pembro plus chemotherapy (chemo) for metastatic squamous non-small-cell lung cancer (sqNSCLC)

Presenter:加泰罗尼亚肿瘤研究所 E. Nadal

CTMS03-Novel Agents and Emerging Therapeutic Strategies 

摘要号:CT039

摘要标题:Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study

Presenter:罗氏有限公司 F. Mussai 

摘要号:CT040

摘要标题:First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer

Presenter:加州大学圣地亚哥分校摩尔斯癌症中心 L. Bazhenova

Clinical Trials Poster Session

PO.CT01.04-Phase I Clinical Trials 1

摘要号:CT053/3

摘要标题:Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)

Presenter:延世大学医学院附属世福兰斯医院延世癌症中心 H. Kim

摘要号:CT054/4 

摘要标题:Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study

Presenter:延世大学医学院癌症中心 B. Cho 

摘要号:CT055/5 

Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation

Presenter:中国医学科学院肿瘤医院 R. Wan 

PO.CT01.01-First-in-Human Phase I Clinical Trials 1

摘要号:CT098/6 

摘要标题:Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors

Presenter:同济大学附属上海市肺科医院 周彩存(现单位:上海市东方医院)

摘要号:CT118/26 

摘要标题:Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors

Presenter:江苏奥赛康药业  T. Song

摘要号:CT119/27 

摘要标题:Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Presenter:华中科技大学同济医学院附属协和医院 董晓荣

PO.CTP01.02-Phase I Clinical Trials in Progress 2

摘要号:CT152/3 

摘要标题:FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations

Presenter:德克萨斯大学安德森癌症中心 X. Le

摘要号:CT154/5  

摘要标题:Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)

Presenter:延世大学医学院癌症中心 S. Lim 

摘要号:CT155/6 

摘要标题:Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer

Presenter:再鼎医药 X. Shen  

摘要号:CT165/16 

摘要标题:A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors

Presenter:吉林省肿瘤医院 程颖 

PO.CT01.02-First-in-Human Phase I Clinical Trials 2 

摘要号:CT185/13 

摘要标题:A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignancies

Presenter:广东省人民医院 吴一龙 

PO.CT02.01-Phase II Clinical Trials 1

摘要号:CT227/27 

摘要标题:Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

Presenter:中山大学肿瘤防治中心 张力

PO.CT03.01-Phase III Clinical Trials

摘要号:CT235/6 

摘要标题:RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC

Presenter:同济大学附属上海市肺科医院 周彩存(现单位:上海市东方医院)

摘要号:CT238/9 

摘要标题:Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial

Presenter:阿斯利康 D. Gale 

要号:CT239/10

摘要标题:IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

Presenter:中国医学科学院肿瘤医院 王洁

PO.CT02.02-Phase II Clinical Trials 2

摘要号:CT246/5 

摘要标题:Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Presenter:上海交通大学附属胸科医院 李子明 

摘要号:CT247/6 

摘要标题:Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study

Presenter:四川科伦博泰生物医药  X. Jin

摘要号:CT248/7

要标题:Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial

Presenter:吉林省肿瘤医院 程颖 

摘要号:CT251/10 

摘要标题:Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

Presenter:中国台湾大学医学院附设医院 J.-H. Yang

摘要号:CT255/14

摘要标题:AdvanTIG-204: A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)

Presenter:四川大学华西医院 Y. Gong

PO.CTP 02.01-Phase II and Phase III Clinical Trials in Progress

摘要号:CT277/7

摘要标题:BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)

Presenter:德克萨斯大学安德森癌症中心 G. Blumenschein, Jr.

摘要号:CT280/10 

摘要标题:FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Presenter:弗吉尼亚癌症专家研究所 A. Spira

摘要号:CT281/11 

摘要标题:The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)

Presenter:麦吉尔大学蒙特利尔校区 J. D. Spicer

摘要号:CT282/12 

摘要标题:MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations

Presenter:"Regina Elena" 国家癌症研究中心 F. Cappuzzo

摘要号:CT283/13

摘要标题:Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%

Presenter:中国台湾大学医学院附设医院  J.-H. Yang

摘要号:CT284/14 

摘要标题:A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2

Presenter:勃林格殷格翰 N. Baktash

责任编辑:肿瘤资讯-Yuno
排版编辑:肿瘤资讯-Yuno


版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。

评论
04月11日
莫静姿
长沙县第一人民医院 | 肿瘤科
非常好
04月04日
张彦
唐山市妇幼保健院 | 妇科
肺癌研究进展抢先看
04月04日
邓新献
大同煤矿集团有限责任公司三医院 | 骨外科
好好学习充实自己